

17 November 2025

ASX Announcement

Bioxyne expands with UK GMP manufacturing site with A\$1,700,000 (£850,000) funding from South of Scotland Enterprise (SOSE)

Bioxyne Limited (ASX: BXN) (“Bioxyne” or “the Company”), through its subsidiary Breathe Life Sciences UK Ltd (BLSUK), is pleased to advise that it has received ~£850,000 in funding commitments from South of Scotland Enterprise, the economic development agency for the South of Scotland, to fit-out and establish its UK medicinal cannabis manufacturing and distribution facility.

Key Highlights

- The funding comprised of a five-year £500,000 loan facility and a grant award of £348,250.
- BLSUK has secured a site in the Scottish Borders region of equivalent size to its Australian facility, to becoming a significant provider of manufacturing and distribution services to the UK medicinal cannabis market. It will also be a key employer in the Scottish Borders region.
- Fit-out of the site and application to the MHRA and Home Offices for the required Licences will be completed in 2026.
- The UK is currently the **second-largest medicinal cannabis market in Europe** after Germany. UK patients have a higher average annual spend on medicinal cannabis, estimated at around **£3,261 (€3,811)** per patient in 2024, compared to approximately £1,342 (€1,563) in Germany.

Sam Watson, CEO, Bioxyne Limited, commented *“We are confident that the UK market, which is seeing tremendous year over year growth will underpin the Company’s continuous growth trajectory. Existing manufacturing infrastructure in UK is insufficient to keep up with local demand, and that’s an opportunity for BLSUK to enter and grow with the market. BLSUK has a growing UK customer base, establishing our UK facility is critical to offering clients our renowned quality and service levels, and replicating our Australian success internationally.”*

Jane Morrison-Ross, Chief Executive of South of Scotland Enterprise, added: *“We are delighted to welcome BLSUK, a key international life sciences company, to our region. The South of Scotland has witnessed inward investment enquiries increase by over 450%, with a surge in innovative life sciences and energy companies. The arrival of BLSUK is further confirmation that our region is the place to do innovative business.”*

Approved by the Board of Bioxyne Limited for release to the ASX.



For further information, please contact:

Bioxyne Limited

Investor Relations

Email: info@bioxyne.com

Phone: +61 2 9078 8180

Sam Watson

Chief Executive Officer

About Bioxyne and Breathe Life Sciences

About Bioxyne Limited

Bioxyne Limited is a licensed Australian pharmaceutical and healthcare company manufacturing and distributing novel medicines, health products and active pharmaceutical ingredients including medicinal cannabis, MDMA, and Psilocybin.

<https://bioxyne.com>

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, health products, and prescription-only cannabis medicines.
- b) Contract drug manufacturing and white label manufacturing of scheduled medicines, therapeutic goods, medical devices, consumer health products, and active pharmaceutical ingredients. BLS manufactures over 200 of Australia’s medicinal cannabis brands.



- c) Import, export, and wholesale of active pharmaceutical ingredients, starting materials, patient-ready medicinal products, and/ or consumer health products in Australia, Japan, UK, USA and Europe.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
 - **United Kingdom:** drwatsoncbd.com
 - **UK / EU:** breathelifesciences.com

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com



For personal use only